TY - JOUR
T1 - The response to substandard and falsified medical products in francophone sub-Saharan African countries: weaknesses and opportunities
AU - Macé, Cécile
AU - Nikiema, Jean-Baptiste
AU - Sarr, Omar Serigne
AU - Ciza Hamuli, Patient
AU - Marini, Roland Djang'eing'a
AU - Neci, Richard Cizungu
AU - Bourdillon Esteve, Pernette
AU - Ravinetto, Raffaella
N1 - FTX; DOAJ; (CC BY 4.0)
PY - 2023
Y1 - 2023
N2 - Assuring the quality of medical products manufactured, imported or distributed in francophone sub-Saharan Africa remains a challenge, despite positive signals like the growing engagement in the benchmarking of regulatory authorities and -particularly- in the establishment of the African Medicines Agency. In this short report, we describe the existing activities to prevent, detect and respond to substandard and falsified products (SF) in this region, either through African multilateral organizations and initiatives led by the World Health Organization, or through the contribution of other stakeholders, such as local universities and procurement agencies. We underline that these emerging local stakeholders may play a pivotal role to guide and inform the national regulatory authorities about the prevalence and patterns of SF medical products, complementing the market surveillance and control, and building awareness of the importance of pharmaceutical quality assurance for public health.
AB - Assuring the quality of medical products manufactured, imported or distributed in francophone sub-Saharan Africa remains a challenge, despite positive signals like the growing engagement in the benchmarking of regulatory authorities and -particularly- in the establishment of the African Medicines Agency. In this short report, we describe the existing activities to prevent, detect and respond to substandard and falsified products (SF) in this region, either through African multilateral organizations and initiatives led by the World Health Organization, or through the contribution of other stakeholders, such as local universities and procurement agencies. We underline that these emerging local stakeholders may play a pivotal role to guide and inform the national regulatory authorities about the prevalence and patterns of SF medical products, complementing the market surveillance and control, and building awareness of the importance of pharmaceutical quality assurance for public health.
U2 - 10.1186/s40545-023-00628-y
DO - 10.1186/s40545-023-00628-y
M3 - A1: Web of Science-article
C2 - 37803394
SN - 2052-3211
VL - 16
JO - Journal of Pharmaceutical Policy and Practice
JF - Journal of Pharmaceutical Policy and Practice
M1 - 117
ER -